Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
17 02 2023
Historique:
pubmed: 6 1 2023
medline: 22 2 2023
entrez: 5 1 2023
Statut: ppublish

Résumé

Lactic acid transport is a key process maintaining glycolytic flux in tumors. Inhibition of this process will result in glycolytic shutdown, impacting on cell growth and survival and thus has been pursued as a therapeutic approach for cancers. Using a cell-based screen in a MCT4-dependent cell line, we identified and optimized compounds for their ability to inhibit the efflux of intracellular lactic acid with good physical and pharmacokinetic properties. To deconvolute the mechanism of lactic acid efflux inhibition, we have developed three assays to measure cellular target engagement. Specifically, we synthesized a biologically active photoaffinity probe (IC

Identifiants

pubmed: 36602435
doi: 10.1021/acschembio.2c00666
doi:

Substances chimiques

Lactic Acid 33X04XA5AT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

296-303

Auteurs

Aarti Kawatkar (A)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Roger A Clark (RA)

Discovery Sciences, R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

Lorna Hopcroft (L)

Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

Debora Ann Roaquin (DA)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Ronald Tomlinson (R)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Andrea M Zuhl (AM)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Gillian M Lamont (GM)

Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

Jason G Kettle (JG)

Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

Susan E Critchlow (SE)

Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

M Paola Castaldi (MP)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Frederick W Goldberg (FW)

Oncology R&D, AstraZeneca, CambridgeCB2 0AA, U.K.

Andrew X Zhang (AX)

Discovery Sciences, R&D, AstraZeneca, Waltham, Massachusetts02451, United States.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae
Animals Humans Nickel Mice Immunotherapy

Classifications MeSH